Shenzhen Neptunus Bioengineering Co., Ltd. (SHENZHEN NEPTUNUS BIOENGINEERIN) Aktie

Shenzhen Neptunus Bioengineering Co., Ltd. engages in the research and development, production, and sale of Chinese patent medicines, infusion products, and western medicine preparations in China. The company provides oryzanol tablets, chlorpheniramine maleate tablets, estazolam tablets, and rifampicin capsules, as well as technical support for generic drug quality consistency evaluation and other medical research and development work. It also distributes drugs, medical devices, and other medical supplies; and offers value-added services for hospitals, medical institutions, and drug retail institutions and distributors. In addition, the company provides drugs in the fields of malignant tumors, cardiovascular and cerebrovascular diseases, neurodegenerative diseases, diabetes, infectious diseases, and multiple diseases, such as respiratory system and digestive system. It develops HW130 injection that completed the Phase I clinical trial for anti-tumor; and NEP018 for anti-tumor. Shenzhen Neptunus Bioengineering Co., Ltd. was founded in 1992 and is headquartered in Shenzhen, China.